All manufacturers of in vitro diagnostic medical devices, or their representatives, shall appoint a person to be responsible for reactovigilance, whose identity and position shall be communicated to the Director General of the Agence nationale de sécurité du médicament et des produits de santé.
Article R5222-11
Updated 1 Nov 2023

